Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and Dulaglutide for MAFLD in T2DM
NCT05140694Phase 4Not yet recruiting
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Dec 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules, Fc-Fusion Proteins
01
Overview
Phase 4, randomised, open-label trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) comparing Empagliflozin, Dulaglutide and Empagliflozin + Dulaglutide (3 arms). Primary endpoints: Changes of HbA1c level at 24 weeks and Changes of CAP score at 24 weeks. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
empagliflozindulaglutide
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05140694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05140694.